Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated-Reference-Cited by-同舟云学术

Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated

Published:2020-12-13 Issue:6 Volume:87 Page:2534-2541
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Gautier‐Veyret Elodie¹^ORCID,Thiebaut‐Bertrand Anne²,Roustit Matthieu¹^ORCID,Bolcato Léa³,Depeisses Julie²,Schacherer Mathilde²,Schummer Gabriel⁴,Fonrose Xavier³,Stanke‐Labesque Françoise¹^ORCID

Affiliation:

1. Inserm, CHU Grenoble Alpes, HP2 Universitaire Grenoble Alpes Grenoble 38000 France

2. Hématologie Clinique CHU Grenoble Alpes France

3. Laboratoire de Pharmacologie, Pharmacogénétique et Toxicologie CHU Grenoble Alpes France

4. Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2 Grenoble France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14661

Reference39 articles.

1. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

2. A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS

3. Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring

4. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

5. The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole;Clinical and Translational Science;2024-07

2. Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization;British Journal of Clinical Pharmacology;2023-10-17

3. Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine;Leukemia & Lymphoma;2023-10-05

4. Can we predict the influence of inflammation on voriconazole exposure? An overview;Journal of Antimicrobial Chemotherapy;2023-10-05

5. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population;Journal of Chemotherapy;2023-08-20